Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-hodgkin lymphoma: Results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab

Luis Fayad, Fritz Offner, Mitchell R. Smith, Gregor Verhoef, Peter Johnson, Jonathan L. Kaufman, Ama Rohatiner, Anjali Advani, James Foran, Georg Hess, Bertrand Coiffier, Myron Czuczman, Eva Giné, Simon Durrant, Michelle Kneissl, Kenneth T. Luu, Steven Y. Hua, Joseph Boni, Erik Vandendries, Nam H. Dang

Research output: Contribution to journal › Article › peer-review

102 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-hodgkin lymphoma: Results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab'. Together they form a unique fingerprint.

Medicine & Life Sciences